Funding momentum Leverage the recent $5M French government grant to position Eligo Bioscience as financially supported and capable of scaling, presenting opportunities to discuss expanded collaborations, pilot programs, and longer-term research partnerships around topical gene delivery.

Topical delivery focus Target engagements around the skin-resident microbiome platform, highlighting potential for partnerships with dermatology, consumer health, and specialized biotech players seeking localized biologics production or microbiome editing capabilities.

Moderate scale, agile With a compact team size (11-50 employees) and modest revenue, present tiered collaboration models, including joint development, sponsored research, and early access programs to align with Eligo’s nimble, high-impact innovation approach.

Broad funding readiness Position offerings that align with government and grant-backed R&D initiatives, emphasizing capabilities that can accelerate grant-led milestones, regulatory-compliant studies, and scalable manufacturing pilots.

Strategic partnerships Identify complementors in microbiome, genomics, and biotherapeutics with similar revenue bands (e.g., smaller biotechs and contract research groups) to enable co-development, licensing, or co-funding of topical gene delivery programs.